Effect of a hormone-releasing intrauterine system (Mirena®) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection

International Journal of Women's Health

Volumn 4, Issue 1, 2012, Pages 175-183

  Maia, Hugo ^a,b   Haddad, Clarice ^a   Casoy, Julio ^a   Maia, Rebeca ^a   Pinheiro, Nathanael ^c   Coutinho, Elsimar M ^a  

^a Centro De Pesquisa E Assistencia Em Reproducao Humana   (Brazil)

^b Itaigara Memorial Day Hospital   (Brazil)

^c Imagepat Anatomic Pathology Laboratory   (Brazil)

Author keywords

Adenomyosis; Aromatase; Cox 2; Endometrium; Levonorgestrel; Mirena

Indexed keywords

AROMATASE; CYCLOOXYGENASE 2; LEVONORGESTREL;

ADENOMYOSIS; ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DYSMENORRHEA; ENDOMETRIUM ABLATION; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAUTERINE CONTRACEPTIVE DEVICE; PROTEIN EXPRESSION; TREATMENT DURATION;

EID: 84864099906     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S30087     Document Type: Article

References (24)

1. Onoglu A, Taskin O, Inal M, et al. Comparison of the long-term histopathologic and morphologic changes after endometrial rollerball ablation and resection: a prospective randomized trial. J Minim Invasive Gynecol. 2007;14(1):39-42.
2. Maia H Jr, Casoy J, Correia T, et al. Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis. Gynecol Endocrinol. 2006;22(10):547-551.
3. Maia H Jr, Pimentel K, Casoy J, et al. Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use. Gynecol Endocrinol. 2007;23(6):320-324.
4. Bukulmez O, Hardy DB, Carr BR, Word RA, Mendelson CR. Inflammatory status influences aromatase and steroid receptor expression in endometriosis. Endocrinology. 2008;149(3):1190-1204.
5. Fechner S, Husen B, Thole H, et al. Expression and regulation of estrogen-converting enzymes in ectopic human endometrial tissue. Fertil Steril. 2007;88(Suppl 4):1029-1038.
6. Maia H Jr, Maltez A, Coelho G, Athayde C, Coutinho EM. Insertion of Mirena® after endometrial resection in patients with adenomyosis. Am Assoc Gynecol Laparosc. 2003;10(4):512-516.
7. Bednarek PH, Jensen JT. Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS. Int J Womens Health. 2010;1:45-58.
8. Maia H Jr, Casoy J, Valente Filho J. Is aromatase expression the cause of endometriosis related infertility? Gynecol Endocrinol. 2009;25: 253-257.
9. Noble LS, Takayama K, Zeitoun KM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. Clin Endocrinol Metab. 1997;82(2):600-606.
10. Smith OP, Jabour HN, Critchley HP. Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum Reprod. 2007;22(5):1450-1456.
11. Maia H, Correia T, Freitas L, Athayde C, Coutinho EM. Cyclooxygenase-2 expression in the endometrium and its relationship to bleeding in users of continuous oral contraceptives. Gynecol Endocrinol. 2006; 22(2):96-100.
12. Critchley HO, Kelly RW, Brenner RM, Baird DT. Antiprogestins as a model for progesterone withdrawal. Steroids. 2003;68(10-13): 1061-1068.
13. Gunes M, Ozdegirmenci O, Kayikcioglu F, Haberal A, Kaplan M. The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study. J Minim Invasive Gynecol. 2008;15(6):735-738.
14. Kriplani A, Singh BM, Lal S, Agarwal N. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet. 2007;97(3):190-194.
15. Koh SC, Singh K. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/ inhibitor systems in women with menorrhagia. J Thromb Haemost. 2007;5(1):133-138.
16. Sharma B, Preston J, Ray C. Microwave endometrial ablation for menorrhagia: outcome at 2 years - experience of a district general hospital. J Obstet Gynaecol. 2004;24(8):916-919.
17. Stamatellos I, Koutsougeras G, Karamanidis D, Stamatopoulos P, Timpanidis I, Bontis J. Results after hysteroscopic management of premenopausal patients with dysfunctional uterine bleeding or intrauterine lesions. Exp Obstet Gynecol. 2007;34(1):35-38.
18. Rizkalla HF, Higgins M, Kelehan P, O'Herlihy C. Pathological findings associated with the presence of a Mirena intrauterine system at hysterectomy. Int J Gynecol Pathol. 2008;27(1):74-78.
19. Deng S, Lang JH, Leng JH, Liu ZF, Sun DW, Zhu L. Effects of levonorgestrel-releasing intrauterine system on pain and recurrence associated with endometriosis and adenomyosis. Zhonghua Fu Chan Ke Za Zhi. 2006;41(10):664-668.
20. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel- releasing IUD. Clin Endocrinol (Oxf). 1982;17(6):529-536.
21. Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;79(3): 189-193.
22. Low S, Smith K - TCRE and Mirena: is the combination better? Gynecol Surg. 2006;3(2):146-147.
23. Sturridge F, Guillebaud J. Gynecological aspects of the levonorgestrel- releasing intra uterine device. Br J Obstet Gynaecol. 1997;104(3): 285-289.
24. Azziz R. Adenomyosis: current perspectives. Obstet Gynecol Clin North Am. 1989;16(1):221-235.